The importance of clarithromycin dose in the management of H-pylori infection:: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole -: Reply

被引：0
|
作者：
Huang, JQ [1 ]
Hunt, RH [1 ]
机构：
[1] McMaster Univ, Med Ctr, Hamilton, ON, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 1999年 / 13卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1693 / 1694
页数：2
相关论文
共 50 条
  • [21] A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole
    Janssen, MJR
    Van Oijen, AHAM
    Verbeek, ALM
    Jansen, JBMJ
    De Boer, WA
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (05) : 613 - 624
  • [22] Proton pump inhibitors (PPI), clarithromycin (C) and amoxicillin (A) or a nitroimidazole (N) for one week.: A meta-analysis of its efficacy on H-pylori eradication.
    Gisbert, JP
    Gonzalez, L
    Calvet, X
    Pajares, JM
    GASTROENTEROLOGY, 2000, 118 (04) : A496 - A496
  • [23] Effects of Different Dosing Schedules of Amoxicillin on the Eradication Rates of Helicobacter pylori by Triple Therapy With a Proton Pump Inhibitor, Amoxicillin, and Either Clarithromycin or Metronidazole
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Yamade, Mihoko
    Uotani, Takahiro
    Sahara, Shu
    Ichikawa, Hitomi
    Yamada, Takanori
    Osawa, Satoshi
    Sugimoto, Ken
    GASTROENTEROLOGY, 2013, 144 (05) : S53 - S54
  • [24] High dose versus standard dose proton pump inhibitor triple therapy for H. pylori eradication.: A meta-analysis
    Villoria, A.
    Garcia, P.
    Calvet, X.
    Gisbert, J. P.
    Vergara, M.
    HELICOBACTER, 2008, 13 (05) : 458 - 458
  • [25] Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance
    Long, Xiaohua
    Chen, Qi
    Yu, Lou
    Liang, Xiao
    Liu, Wenzhong
    Lu, Hong
    HELICOBACTER, 2018, 23 (03)
  • [26] Impact of Efficacies of Triple Therapy Using Lafutidine Plus Amoxicillin-Metronidazole for Proton Pump Inhibitor-Amoxicillin-Clarithromycin Treatment Failures for Helicobacter pylori Infection
    Kudo, Takahiko
    Fujinami, Haruka
    Hosokawa, Ayumu
    Takahara, Terumi
    Sugiyama, Toshiro
    GASTROENTEROLOGY, 2009, 136 (05) : A341 - A341
  • [27] Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H-pylori (Hp) infection.
    van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    GASTROENTEROLOGY, 1998, 114 (04) : A323 - A323
  • [28] What is the optimal length of proton pump inhibitor-based triple therapies for H-pylori?: A cost-effectiveness analysis
    Calvet, X
    Gené, E
    López, T
    Gisbert, JP
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (07) : 1067 - 1076
  • [29] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H-pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin
    Furuta, T
    Shirai, N
    Xiao, F
    Takashita, M
    Sugimoto, M
    Kajimura, M
    Ohashi, K
    Ishizaki, T
    HEPATO-GASTROENTEROLOGY, 2003, 50 (54) : 2274 - 2278
  • [30] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan
    Dojo, M
    Azuma, T
    Saito, T
    Ohtani, M
    Muramatsu, A
    Kuriyama, M
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) : 671 - 675
12345